VEGF and medicine concentration in serum and eye of patients with age-related macular degeneration before and after anti-VEGF therapy

Concentration of vascular endothelial growth factor and medicine in serum and aqueous humor of patients with neovascular age-related macular degeneration before and after anti-VEGF therapy - Serum and ocular VEGF and medicine concentration with age-related macular degeneration

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041817

Enrollment

Registered

2020-09-17

Start date

2020-09-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

age-related macular degeneration

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with neovascular age-related macular degeneration, male or female, people 50 years old or older with informed consent.

Exclusion criteria

Exclusion criteria: Patients are judged to be inappropriate by doctors in charge. Patients who would like to withdraw their consent.

Design outcomes

Primary

Measure	Time frame
The serum concentration of vascular endothelial growth factor before, 1 week and 1, 2, 3, 4, 5-month after the intravitreal injection of anti-vascular endothelial growth factor	—

Secondary

Measure	Time frame
The correlation of change in best corrected visual acuity or central retinal subfield thickness and serum concentration of vascular endothelial growth factor before, 1 week and 1, 2, 3, 4, 5- month after the injection of anti-vascular endothelial growth factor	—

Countries

Japan

Contacts

Public ContactTomoko Sawada

Shiga University of Medical Science Department of Ophthalmology

tsawada@belle.shiga-med.ac.jp0775482276

Outcome results